{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:04:47Z","timestamp":1781103887894,"version":"3.54.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to identify predictors of suboptimal response to efgartigimod in patients with generalized myasthenia gravis (gMG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-center retrospective study, 35 gMG patients treated with efgartigimod were categorized into responders (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f25) and non-responders (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f10). Responders were defined by a reduction of &amp;gt;2 points in MG-ADL or &amp;gt;3 points in QMG score after one cycle, whereas non-responders showed improvement below these thresholds and subsequently responded to eculizumab. Demographic, clinical, and serological features were compared using univariate and multivariate analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Non-responders had higher baseline gross motor and respiratory sub-scores. Univariate analysis revealed that thymoma, non-thymoma tumors, thyroid disease, and other autoimmune diseases were more common in non-responders. Multivariate analysis indicated that combinations of these factors were associated with a high predicted probability of poor response (up to 97.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Comorbidities including thymoma, other tumors, thyroid disease, and additional autoimmune disorders may predict reduced response to efgartigimod in gMG patients. Systematic evaluation of these factors could help optimize treatment selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1715486","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:53:48Z","timestamp":1762433628000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective analysis of predictive factors"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhenyu","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"},{"key":"ref4","volume-title":"Efgartigimod for treating antibody-positive generalised myasthenia gravis","year":"2025"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1007\/s10072-025-08096-9","article-title":"Efgartigimod improves non-AChR generalized myasthenia gravis: a real world experience","volume":"46","author":"Antozzi","year":"2025","journal-title":"Neurol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","article-title":"Myasthenia gravis in 2025: five new things and four hopes for the future","volume":"272","author":"Binks","year":"2025","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"123264","DOI":"10.1016\/j.jns.2024.123264","article-title":"Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis","volume":"466","author":"Dewilde","year":"2024","journal-title":"J Neurol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK'S first real-world experience","volume":"96","author":"Moniz Dion\u00edsio","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1407418","DOI":"10.3389\/fneur.2024.1407418","article-title":"Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients","volume":"15","author":"Wang","year":"2024","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208774","article-title":"Long-term effectiveness and safety of eculizumab in patients with generalized myasthenia gravis (gMG): real-world data from Japan","author":"Murai","year":"2025"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"17562864251319656","DOI":"10.1177\/17562864251319656","article-title":"Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes","volume":"18","author":"Jin","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"17562864241309431","DOI":"10.1177\/17562864241309431","article-title":"Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study","volume":"17","author":"Jin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.jtho.2025.04.014","article-title":"Perioperative safety and efficacy of Efgartigimod for Thymoma-associated myasthenia gravis: a prospective, multicenter, phase II clinical trial","volume":"20","author":"Wang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Utsugisawa","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"17562864231213240","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1486659","DOI":"10.3389\/fneur.2024.1486659","article-title":"Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation","volume":"15","author":"Shi","year":"2024","journal-title":"Front Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11748-007-0185-8","article-title":"Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis","volume":"56","author":"Okumura","year":"2008","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00595-012-0318-2","article-title":"Thymus, thymoma and myasthenia gravis","volume":"43","author":"Fujii","year":"2013","journal-title":"Surg Today"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mus.20526","article-title":"Eosinophilia, myositis, and myasthenia gravis associated with a thymoma","volume":"34","author":"Avni","year":"2006","journal-title":"Muscle Nerve"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1715486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:53:49Z","timestamp":1762433629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1715486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":26,"alternative-id":["10.3389\/fneur.2025.1715486"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1715486","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1715486"}}